The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany.

Banyan Biomarkers was founded in 2002 by Ron Hayes, PhD , Kevin Wang, PhD, and Nancy Denslow, PhD to create the first Point of Care (POC) Blood Test to diagnose traumatic brain injury (TBI). Currently no blood test exists for use by physicians to detect the presence and severity of brain trauma. Banyan Biomarkers’ research has identified unique and proprietary biomarkers present in the patient’s blood following injury to the brain. The detection and quantification of these biomarkers may provide early indications of brain trauma essential for earlier intervention and management.

Warner-Lambert Co. used to manufacture and market pharmaceuticals, consumer health care products & confectionery. Its pharmaceutical products were ethical pharmaceuticals, biological products and hard-gelatin capsules. Its consumer health products were a wide range of products like oral care mouthwash/dental rinses, toothpaste, effervescent denture cleaning tablets, upper respiratory cold & sinus preparations, antihistamines, allergy products and cough syrups/suppressants. The company was headquartered in Morris Plains, NJ.

Asklepios BioPharmaceutical is a biotechnology company developing adeno-associated virus (AAV) gene therapies for genetic disorders and other rare diseases. It offers proprietary AAV technology, manufacturing capabilities, and a robust pipeline of in-house clinical programs for clients in the medical biopharmaceutical industry. Its pipeline includes clinical-stage programs in Pompe disease and congestive heart failure and a diverse preclinical portfolio of therapeutics targeting neuromuscular, CNS, and other diseases, as well as out-licensed clinical indications for hemophilia and Duchenne muscular dystrophy. The company’s gene therapy platform includes Pro10, an industry-leading proprietary cell line manufacturing process, and an extensive AAV capsid, and promoter library. Asklepios BioPharmaceutical was founded in 2001 and is headquartered in Research Triangle Park, North Carolina.

Develops pharmaceutical products

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

ZyStor Therapeutics, Inc. develops innovative therapeutics. It offers enzyme replacement therapies for the treatment of lysosomal storage diseases. The company was founded by Brian L. Clevinger, James S. Manuso and Allan R. Goldberg and is headquartered in Milwaukee, WI.

ChromoTek GmbH develops immunologic research and detection reagent and tools for proteomics and cell biology. The company was founded in 2008 and is based in Planegg-Martinsried, Germany.

Anima Cell Metrology, Inc. engages in the development of novel technologies to monitor protein synthesis in living cells. The company was founded by Zeev Smilansky and is headquartered in Bernardsville, NJ.

Ramot at Tel Aviv University Ltd. operates as a technology transfer company of Tel Aviv University (TAU). It provides legal and commercial frameworks for inventions made by TAU faculty, students, and researchers. The firm licenses the university's intellectual property to third parties through agreements; facilitates collaborative research partnerships between business partners and TAU researchers; establishes a company; and forms joint ventures that promote TAU technologies. The company was founded in 1973 and is headquartered in Tel Aviv, Israel.

Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. It has a global partnership with Roche for developing novel CRACM inhibitors, an oral calcium released activated calcium modulator ion channel inhibitor program that is in the lead optimization stage for the treatment of autoimmune diseases. The company also retains rights in various indications and markets to its other drug candidates and programs, which include STA-9090, an Hsp90 inhibitor that is in Phase 1 development; elesclomol, an oxidative stress inducer for the treatment of cancer; and apilimod, an oral IL-12/23 inhibitor, which is in Phase 2 for rheumatoid arthritis. In addition, Synta Pharmaceuticals Corp. is developing STA-9584, a vascular disrupting agent that is in preclinical development. The company was incorporated in 2000 and is based in Lexington, Massachusetts.

Andes Biotechnologies is a leading nucleic acid-based drug discovery and development company focused on solid tumor cancers. The Company has discovered two novel families of long non-coding RNAs: sense (S-RNA) and antisense (AS-RNA). Both are present in all human cells, are synthesized in the mitochondria and migrate to the nucleus. The proprietary technology developed by Andes Biotechnologies is based on oligonucleotide drugs that target the novel long non-coding regulatory RNAs in tumor cells inducing apoptosis. Andes Biotechnologies has an active investigational new drug (IND) application in the United States and is currently engaged in the clinical development of its lead drug Andes-1537. Andes Biotechnologies is supported by a proven and experienced management team, a robust network of key national and international collaborators in the cancer field, and has an extensive intellectual property portfolio. Andes Biotechnologies was founded in 2008 and is located in Santiago, Chile.

HistoRx is developing theranostic solutions to towards individualized patient care. HistoRx's proprietary technology delivers objective and reproducible multiparametric analysis of proteins in tissue, providing insights into cancer treatment.

The University of Iowa Research Foundation (UIRF) - a 501C3 corporation - commercializes University of Iowa developed technologies and inventions through licensing and new venture formation, and manages the subsequent revenue stream.

Beckman Coulter, Inc. manufactures and distributes biomedical testing instrument systems and general biomedical research products. It develops and markets products that simplify, automate and innovate complex biomedical testing. The firm’s systems operate in both diagnostics and life sciences laboratories on seven continents. Its products improve the productivity of medical professionals and scientists, supplying critical information for improving patient health and delivering trusted solutions for research and discovery. The company was founded in 1935 by Arnold O. Beckman and is headquartered in Brea, CA.

ProteoSys AG offers biotechnology research services. It provides solutions for the drug development process focusing on target system discovery, target validation, modes of action, studies of side effects and toxicology. The company was founded by Andr�� Schrattenholz and Helmut Matthies in 2000 and is headquartered in Mainz, Germany.